For example, treatments that alleviate selective pressure of ADT, such as BAT or non-AR-related therapy, such as 177Lu-PSMA-617 in combination with AR-targeted drugs, may be a good strategy to outsmart PCa’s adaptive ability to its microenvironment. Here, AR is linked to posterior cortical atrophy.